<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611569</url>
  </required_header>
  <id_info>
    <org_study_id>17699A</org_study_id>
    <nct_id>NCT03611569</nct_id>
  </id_info>
  <brief_title>Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how&#xD;
      well it is tolerated, how the drug effects the body and what the body does to the drug in&#xD;
      healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">July 26, 2021</completion_date>
  <primary_completion_date type="Actual">July 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>From dosing to Day 84</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, blood closure time and ECG parameters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>From dosing to Day 84</time_frame>
    <description>Area under the Lu AF82422 plasma concentration curve from zero to time t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From dosing to Day 84</time_frame>
    <description>Maximum observed plasma concentration of Lu AF82422</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>From dosing to Day 84</time_frame>
    <description>Clearance of Lu AF82422</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Lu AF82422</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A:&#xD;
Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)&#xD;
Part B:&#xD;
Cohort B1, B2, B3: 24 patients with Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A:&#xD;
Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)&#xD;
Part B:&#xD;
Cohort B1, B2, B3: 24 patients with Parkinson's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF82422</intervention_name>
    <description>Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose</description>
    <arm_group_label>Lu AF82422</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo - concentrate for solution for infusion, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
        - Men and women ≥18 and ≤55 years of age with a body mass index (BMI) ≥18 and ≤32 kg/m2&#xD;
        (non-Japanese subjects) and ≥18 and ≤28 kg/m2 (Japanese subjects)&#xD;
&#xD;
        Patients with Parkinson's disease:&#xD;
&#xD;
          -  Men and women with a clinical diagnosis of idiopathic Parkinson's disease, Hoehn and&#xD;
             Yahn (H&amp;Y, stage 1-3)&#xD;
&#xD;
          -  For a minimum of three months prior to enrolment, Parkinson's disease symptoms have&#xD;
             been stable and is anticipated to be stable during the study duration as judged by the&#xD;
             PI&#xD;
&#xD;
          -  If on Parkinson's disease treatment the dose must be stable for a minimum of three&#xD;
             months prior to enrolment and is anticipated to be stable during the study duration as&#xD;
             judged by the PI&#xD;
&#xD;
          -  ≥40 and ≤80 years of age&#xD;
&#xD;
          -  BMI ≥18 and ≤35 kg/m2&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Atypical Parkinsonism&#xD;
&#xD;
          -  Clinically relevant structural brain abnormality, as assessed using MRI&#xD;
&#xD;
          -  Mild cognitive impairment, measured as a Montreal cognitive assessment (MoCA) score&#xD;
             =&lt;21&#xD;
&#xD;
          -  Any past or current treatment with an active vaccine targeting alpha-synuclein&#xD;
&#xD;
          -  Any past or current treatment with a monoclonal antibody within the last 12 months&#xD;
&#xD;
        Other in- and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group (CCTMG)</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserach Center of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel, Early Phase Clinical Unit (EPCU), Harbor Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

